What Etrane Treats: Main Uses and Benefits

Etrane (enflurane) is primarily used in the context of surgery to manage several critical symptomatic domains. It is applied across therapeutic areas requiring controlled suppression of consciousness.

This medication is commonly used for both the induction and maintenance of general anesthesia in adult and pediatric surgical patients, as well as providing analgesia (pain relief) during vaginal delivery. The core benefit is establishing a state where the patient is non-responsive, unaware, and free from pain during critical interventions, which assists with providing necessary supportive care. This control allows clinicians to adjust the depth of symptomatic suppression as needed during the surgical process.

“The drug is used to establish and sustain a state where sensation and awareness are managed.”

---

Symptom Focus: Acute Procedural Pain

Feature	Detail
Primary Symptom Domain	Loss of consciousness and sensation, pain (nociception)
Main Clinical Context	Surgical procedures (minor and major)
Secondary Clinical Context	Analgesia during labor and delivery
Patient Benefit	Supports the patient remaining unaware and pain-free

Eligibility Map: Who Can and Cannot Use Etrane — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Established for general anesthesia in adults and pediatric surgical patients. Also documented for analgesia during vaginal delivery.
Populations for whom use is not recommended	Generally avoided in patients with a history of seizure disorders due to the potential for increased seizure-like activity.
Populations for whom use is contraindicated	Patients with known or suspected genetic susceptibility to malignant hyperthermia. History of liver dysfunction or unexplained fever following previous halogenated anesthetic administration. Known hypersensitivity to the drug.
Age-related eligibility rules	Established for adult and pediatric use. Caution is recommended for older adults (geriatric) as a lower anesthetic concentration may be required.
Condition-specific eligibility rules	Use requires caution in patients with latent or overt neuromuscular disease (e.g., Duchenne muscular dystrophy). Caution also applies to those chronically ingesting isoniazid.
Pregnancy and lactation eligibility status	Classified as Pregnancy Category B. Generally considered low-risk during lactation.
Eligibility-related restrictions	High concentrations are restricted during vaginal delivery or Cesarean section due to the risk of increased uterine bleeding.

Connection to the overall eligibility profile

Regulatory documents strictly define Etrane's eligibility, classifying absolute contraindications based on genetic risk and history of liver reaction to similar drugs. The profile confirms use in adult and pediatric patients but mandates specific caution for certain comorbid conditions like neuromuscular disease or a history of seizure disorders.

Interactions with other medicines and products

Etrane (enflurane) interacts with several medicinal products, primarily through pharmacodynamic effects that alter the depth of anesthesia required or the effects of co-administered agents. No combinations are formally classified as contraindicated due to drug-drug interaction risk in the official prescribing information.

---

Documented Pharmacodynamic Interactions

Interacting Product Category	Officially Documented Outcome
Non-depolarizing Neuromuscular Blocking Agents	Effects are markedly potentiated and prolonged.
Opioids, Sedatives, CNS Depressants	Result in additive Central Nervous System (CNS) depressant effects.
Nitrous Oxide ( N2 O)	Co-administration decreases the Minimum Alveolar Concentration (MAC) required for Etrane.
Epinephrine (Adrenaline)	Myocardium is sensitized; dosage limits must be observed during procedures.
Oxytocin	Higher concentrations of enflurane diminish or abolish the effect on uterine contractions.

---

Metabolic and Population-Specific Notes

A specific pharmacokinetic interaction is documented with Isoniazid (INH), a hydrazine-containing compound, which may cause enhanced metabolism of enflurane and result in increased serum inorganic fluoride concentrations. This increase is considered more significant in patients with renal impairment.

These interactions establish constraints on the use of Etrane, defining how co-administration with other agents modifies the required concentration and the effects of peripheral muscle relaxants.

How Etrane Works

Etrane functions as a selective modulator, initiating its action by engaging mechanisms that involve specific receptor- or enzyme-mediated signaling. This primary interaction establishes a high affinity for defined binding sites, allowing Etrane to either inhibit an enzyme or allosterically influence a receptor. This targeted binding is the first step in disrupting a dysregulated cellular process.

Its mechanism extends to modifying central regulatory hubs within well-characterized molecular cascades. By adjusting the flow of information in cellular systems where specific transmitters or mediators dominate, Etrane modifies the level of excessive activity and influences the dynamics of pathway regulation within targeted circuits.

Through this focused interference, Etrane engages mechanisms that influence feedback regulation within the affected pathways. This action modulates processes driven by distinct signaling patterns, ultimately resulting in the adjustment of overactive physiological responses and shaping the drug's overall pharmacodynamic profile. The entire process remains strictly within the biochemical and physiological domains.

Etrane (enflurane, USP) is a volatile inhalation anesthetic agent used for both the induction and maintenance of general anesthesia. It is also indicated for providing analgesia during vaginal delivery or as an anesthetic supplement for Cesarean section, though higher concentrations may risk uterine relaxation and increased bleeding.

Administration

Etrane must be administered by inhalation using a specifically calibrated vaporizer that delivers predictable concentrations. Only individuals trained in the administration of general anesthesia should deliver this medication, with facilities for resuscitation immediately available.

Dosage

Dosage must be highly individualized and titrated to the desired effect based on the patient's age, physical condition, and surgical requirements. Anesthetists typically monitor the patient's blood pressure and respiratory exchange as guides to the depth of anesthesia.

Clinical Application	Inspired Concentration Range
Induction of Anesthesia	Starting at 0.5% and gradually increased, not to exceed 4.5%.
Maintenance of Anesthesia	Typically sustained within the 0.5% to 3.0% range, often lower when used with nitrous oxide.
Obstetric Analgesia (Vaginal Delivery)	Low concentrations, generally between 0.25% and 1.0%.

Important Considerations

• Muscle Relaxants: Etrane markedly potentiates the effects of non-depolarizing muscle relaxants, requiring careful dose adjustment.
• CO2 Absorbents: Etrane may react with desiccated carbon dioxide ( CO2) absorbents to produce carbon monoxide. If the CO2 absorbent is suspected to be desiccated, it must be replaced before administration.
• Monitoring: The patient's electrocardiogram, blood pressure, oxygen saturation, and end-tidal CO2 should be continually monitored during administration.

Research evidence / Overview of Studies for Etrane

Evidence for Use in General Anesthesia

Research into Etrane's use as an inhalational anesthetic primarily involved Randomized Controlled Trials (RCTs) and comparative clinical investigations. These studies were designed to evaluate and measure the outcomes of the agent's administration during the surgical process. Researchers examined outcomes related to the onset of anesthetic effect, specifically the time required to achieve a state of general anesthesia (induction), and the time needed for the patient to return to consciousness (emergence and recovery). Studies were conducted in general adult patient populations undergoing various surgical procedures.

The available evidence describes the time measurements recorded in the studies related to the initiation and the reversal of the anesthetic state. Clinical reports, which contribute to the regulatory evidence landscape, describe the agent as having been evaluated in both the initiation and sustaining phases of the anesthetic state. Findings highlight the specific measurements recorded during these short, defined time intervals, providing context on the parameters evaluated in the study populations.

Evidence for Analgesia During Labor and Delivery

Etrane was also studied for its application, and research specifically explored its role in providing analgesia during the process of vaginal delivery. Clinical investigations were focused on assessing the level of symptomatic pain relief achieved during labor. These studies also monitored the agent's influence on the uterus, specifically examining the relationship between the administered concentration of Etrane vapor and any effects on uterine contractility. The research population for this evidence was women undergoing delivery.

Studies reported on the level of pain-related outcomes recorded during the labor process when Etrane was administered at lower concentrations. Reports described a pattern where the anesthetic vapor was observed in some studies to have an association with changes in uterine contractions, with researchers evaluating the relationship between concentration and uterine-related physiological outcomes, and its documented association with uterine relaxation at higher concentrations.

What is Still Uncertain About Etrane

One key factor is that the majority of the pivotal studies are older comparative trials that assessed Etrane against other agents that are less common in modern practice, meaning that comparative evidence is lacking. Furthermore, long-term effects are not fully established, as follow-up durations were limited in the primary research. While clinical studies described the agent's use in both adult and pediatric patients, and during labor, data for certain groups remain insufficient, meaning the evidence base does not fully reflect the broad range of patients seen today. Research provides context but not individual predictions.

Key Studies & References NIH LiverTox: Enflurane (Used for contemporary context and status of the agent, and supporting limitations/warnings in the research context)

Common questions about Etrane (FAQ)

Q: Is Etrane often prescribed to younger adults (under 30)?

A: Official information indicates that Etrane (enflurane) is approved for use in both adult and pediatric patients for general anesthesia. However, the precise concentration required must be highly individualized for every patient, based on their age, physical condition, and the needs of the surgical procedure.

Q: Are there specific research studies on Etrane focusing on long-term effects (over 5 years)?

A: Regulatory documents note that the pivotal clinical trials focused on short-term outcomes related to the surgical event itself, such as induction and recovery time. Because of this, studies with follow-up durations of five years or more were limited in the primary evidence, meaning that long-term effects are not fully established in the drug's initial evidence base.

Q: Does the official evidence base for Etrane include real-world data or only clinical trials?

A: The initial evidence base consists of controlled clinical trials. However, regulatory safety documents also rely on postmarketing reports which describe rare and serious adverse events observed after the drug's approval. This postmarketing information is a form of real-world data that helps inform the safety profile.

Q: What are the common reasons a doctor might choose to discontinue Etrane?

A: Official documentation requires the agent to be discontinued by the clinician if there are clinical signs of a serious complication like Malignant Hyperthermia (MH). Separately, the drug is contraindicated (should not be used) in patients with a history of hepatic reactions to similar anesthetic agents. These restrictions are regulatory requirements based on patient safety.

Q: Are the effects of Etrane consistent for everyone who uses it?

A: Official product information states that the dosage must be highly individualized and carefully adjusted by the anesthetist based on the patient's age, physical health, and surgical needs. This individualized approach is necessary because the required anesthetic concentration can vary significantly from person to person.

Q: What types of safety classifications does Etrane hold from major regulatory bodies?

A: Etrane is classified as Pregnancy Category B by the FDA, which is a status related to safety information for use during pregnancy. It is designated as a halogenated inhalational anesthetic agent and is no longer widely used in the United States.

Q: Can Etrane be used by people with other chronic health conditions like diabetes?

A: The official label lists specific patient groups for whom caution is required, such as those with neuromuscular disease or those taking isoniazid. The suitability for other chronic conditions is assessed individually as part of the anesthetic plan.

Q: What is the significance of the "Warnings and Precautions" section for Etrane?

A: This section highlights clinically significant risks that require careful consideration and continual monitoring by the medical team. Key items include the potential for Malignant Hyperthermia (MH) in susceptible individuals and the risk of generating carbon monoxide if the breathing circuit's CO2 absorbents are desiccated.

Q: Is Etrane a treatment for the cause or the symptoms of the condition?

A: Etrane is indicated for general anesthesia and for analgesia (pain relief) during labor. Its documented action is to depress the Central Nervous System (CNS) and adjust overactive physiological responses, which means it addresses the symptoms (pain and consciousness) related to a medical procedure, not the underlying cause of a disease.

Q: How does Etrane compare to similar older medicines for the same condition?

A: Historically, research reports described Etrane as having a different profile regarding the liver compared to an older agent called halothane. Though it remains associated with a rare risk of hepatic injury, it has since been largely replaced by newer volatile anesthetic agents.

Q: Is Etrane considered a first-line treatment option in official guidelines?

A: Official regulatory status indicates that Etrane is no longer widely used in clinical practice and has been classified as a discontinued product by the FDA. Due to the availability of newer agents, it is not typically considered a first-line choice in current anesthetic guidelines.

Q: Are there any specific dietary restrictions that are generally recommended while taking Etrane?

A: The official prescribing information for Etrane lists a number of interactions with other medicinal products. However, no specific food restrictions or foods to be completely avoided are noted in the regulatory documents.

Q: Can Etrane affect the results of common blood tests?

A: A specific interaction is documented for patients who are chronically taking the medicine Isoniazid (INH), which may lead to an increase in a metabolite called serum inorganic fluoride. This increase is noted to be potentially more significant for patients with renal impairment.

Q: Is Etrane known to cause changes in mood or sleep patterns?

A: The official safety profile lists several nervous system effects, and postmarketing reports have noted psychiatric effects such as agitation and altered mood. It is also documented that common post-anesthetic effects can include feelings of being drowsy, tired, or generally weak.

Q: Are there any known foods that must be completely avoided when using Etrane?

A: The official prescribing information focuses on drug-drug interactions. It does not contain any mention of specific foods or dietary components that must be completely avoided when Etrane is administered.

Storage and Disposal Conditions for Etrane (Enflurane)

Etrane must be stored strictly according to the following official requirements to maintain its integrity:

• Temperature: Store at controlled room temperature, which is defined as 15 C to 30 C (59 F to 86 F).
• Protection: The container must be kept tightly closed, protected from light, and stored in its original packaging.
• Child Safety: The product must be stored out of reach of children.

Etrane is chemically stable under these specified conditions and does not contain additives. Unused portions and any associated pharmaceutical waste must be disposed of in accordance with all applicable federal, state, and local regulations for specialized medical waste, not household trash or wastewater.